



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



33-BCRP Inhibitor

Item No. 39403

Formal Name:	N-(4-azidophenyl)-2-(pyridin-4-yl)quinazolin-4-amine
Synonym:	33-Breast Cancer Resistance Protein Inhibitor
MF:	C ₁₉ H ₁₃ N ₇
FW:	339.4
Purity:	≥98%
UV/Vis.:	λ _{max} : 249 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

33-BCRP inhibitor is supplied as a solid. A stock solution may be made by dissolving the 33-BCRP inhibitor in the solvent of choice, which should be purged with an inert gas. 33-BCRP inhibitor is soluble in DMSO and methanol.

Description

33-BCRP inhibitor is an inhibitor of breast cancer resistance protein (BCRP).¹ It sensitizes mitoxantrone-resistant H460/MX20 lung cancer cells to mitoxantrone-induced cell death alone and in combination with UV radiation. 33-BCRP inhibitor also sensitizes KB-C2 epidermal carcinoma cells overexpressing P-glycoprotein (P-gp), also known as multidrug resistance protein (MDR), to colchicine-induced cell death. It increases intracellular accumulation of mitoxantrone (Item No. 14842) in H460/MX20 cells when used at a concentration of 5 μM.

Reference

1. Cai, C.-Y., Teng, Q.-X., Murakami, M., *et al.* Design, synthesis and biological evaluation of quinazolinamine derivatives as breast cancer resistance protein and p-glycoprotein inhibitors with improved metabolic stability. *Biomolecules* **13**(2), 253 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/28/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM